Circulating PSA-containing macrophages: a tool to distinguish indolent from aggressive prostate cancer? A pilot study.

Circulating PSA-containing macrophages: a tool to distinguish indolent from aggressive prostate cancer? A pilot study. - PSA in macrophages

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33803

Enrollment

150

Registered

2009-05-14

Start date

2009-07-20

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Men >= 18 years - Histological confirmed adenocarcinoma of the prostate - Localized prostate cancer - Scheduled for radical prostatectomy - Given informed consent

Exclusion criteria

Exclusion criteria: - Metastatic disease - Patient not able to understand the patient information

Design outcomes

Primary

Measure	Time frame
The difference in the number of activated PSA positive macrophages (preoperatively) between patients with significant and insignificant cancers (insignificant defined as	—

Secondary

Measure	Time frame
- The difference in the number of activated PSA positive macrophages (at 1 week, 6 weeks and 6 months postoperatively) between patients with significant and insignificant cancers. - The difference in the number of activated PSA positive macrophages (preoperatively, or at 1 week, 6 weeks, 6 months postoperatively) between patients with biochemical recurrence (serum PSA at 3 months and 1 year postoperatively > 0.2 ng/ml)	—

Measure

Time frame

- The difference in the number of activated PSA positive macrophages (at 1 week, 6 weeks and 6 months postoperatively) between patients with significant and insignificant cancers. - The difference in the number of activated PSA positive macrophages (preoperatively, or at 1 week, 6 weeks, 6 months postoperatively) between patients with biochemical recurrence (serum PSA at 3 months and 1 year postoperatively > 0.2 ng/ml)

—

Countries

Netherlands

Outcome results